Overall Survival of Children and Adolescents with Mature B Cell Non-Hodgkin Lymphoma Who Had Refractory or Relapsed Disease During or After Treatment with FAB/LMB 96: A Report from the FAB/LMB 96 Study Group

Overview

Journal Br J Haematol

Specialty Hematology

Date 2018 Jul 10

PMID 29984828

Citations 22

Authors

Mitchell Cairo

Anne Auperin

Sherrie L Perkins

Ross Pinkerton

Lauren Harrison

Stanton Goldman

Catherine Patte

Affiliations

Soon will be listed here.

Abstract

We determined the risk factors associated with poor survival in children and adolescents with de novo mature B cell non-Hodgkin lymphoma (B-NHL) who had refractory or relapsed disease during or after the French-American-British mature lymphoma B (FAB/LMB) 96 multi-agent chemotherapy. Among the 1 111 registered on study, 104 patients (9·4%) had refractory disease or disease relapse after first complete remission. Among these 104 patients, 28 (27%) patients had refractory disease and 76 (73%) had relapsed disease. The estimated 1- and 2-year overall survival (OS) (95% confidence interval) was 31·5% (23·3-41·0%) and 22·3% (15·3-31·4%), respectively. Prognostic analysis of OS using a Cox multivariate model showed that factors independently associated with OS included lactate dehydrogenase ≥2 upper normal limit [hazard ratio (HR) = 2·86 (1·57-5·2), P = 0·0006]; time to failure (>6 months) [HR = 0·59 (0·36-0·97), P = 0·038]; and failure in bone marrow [HR = 2·78 (1·65-4·68), P = 0·0001]. New therapeutic strategies are required to significantly reduce refractory disease and disease relapse in patients with newly diagnosed mature B-NHL and, more importantly, there is a critical need to develop novel retrieval approaches in patients with chemotherapy-resistant disease.

Citing Articles

Use of rituximab in mature, high-grade and advanced-stage pediatric B-lineage non-Hodgkin lymphomas: a systematic review, meta-analysis and the Brazilian reality.

de Castro A, de Oliveira L, de Andrade D, Carbone E, Rosati R Front Pediatr. 2025; 13:1532274.

PMID: 39902063 PMC: 11789686. DOI: 10.3389/fped.2025.1532274.

Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies.

Malfona F, Testi A, Chiaretti S, Moleti M Blood Lymphat Cancer. 2024; 14:1-15.

PMID: 38510818 PMC: 10949171. DOI: 10.2147/BLCTT.S407804.

CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?.

Kinoshita H, Bollard C, Toner K Semin Hematol. 2024; 60(5):329-337.

PMID: 38336529 PMC: 10964476. DOI: 10.1053/j.seminhematol.2023.11.007.

Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant.

Pasvolsky O, Bassett R, Ghanem S, Cuglievan B, Tewari P, Hosing C BMC Cancer. 2023; 23(1):1258.

PMID: 38124057 PMC: 10734180. DOI: 10.1186/s12885-023-11712-6.

Optimal dosage of rituximab for children with Burkitt lymphoma.

Huang S, Jin L, Yang J, Zhang M, Zhang Y, Peng Y Ann Hematol. 2023; 103(3):893-903.

PMID: 38091052 DOI: 10.1007/s00277-023-05568-w.

References

Goldman S, Smith L, ANDERSON J, Perkins S, Harrison L, Geyer M . Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia. 2012; 27(5):1174-7. PMC: 4539148. DOI: 10.1038/leu.2012.255. View

Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R . Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2006; 109(7):2773-80. PMC: 1852229. DOI: 10.1182/blood-2006-07-036673. View

Mussolin L, Pillon M, Conter V, Piglione M, Lo Nigro L, Pierani P . Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood. J Clin Oncol. 2007; 25(33):5254-61. DOI: 10.1200/JCO.2007.11.3159. View

Spreafico F, Massimino M, Luksch R, Casanova M, Cefalo G, Collini P . Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children. J Clin Oncol. 2002; 20(12):2783-8. DOI: 10.1200/JCO.2002.08.088. View

Patte C, Philip T, Rodary C, Zucker J, Behrendt H, Gentet J . High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol. 1991; 9(1):123-32. DOI: 10.1200/JCO.1991.9.1.123. View

Poirel H, Cairo M, Heerema N, Swansbury J, Auperin A, Launay E . Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Leukemia. 2008; 23(2):323-31. PMC: 2988438. DOI: 10.1038/leu.2008.312. View

Jourdain A, Auperin A, Minard-Colin V, Aladjidi N, Zsiros J, Coze C . Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective "Lymphomes Malins B" protocols. A Société Française des Cancers de l'Enfant study. Haematologica. 2015; 100(6):810-7. PMC: 4450627. DOI: 10.3324/haematol.2014.121434. View

Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I . The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2004; 105(3):948-58. DOI: 10.1182/blood-2004-03-0973. View

Griffin T, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R . A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008; 52(2):177-81. PMC: 2728935. DOI: 10.1002/pbc.21753. View

10.

Gerrard M, Cairo M, Weston C, Auperin A, Pinkerton R, Lambilliote A . Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008; 141(6):840-7. DOI: 10.1111/j.1365-2141.2008.07144.x. View

11.

Bowman W, Shuster J, Cook B, Griffin T, Behm F, Pullen J . Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol. 1996; 14(4):1252-61. DOI: 10.1200/JCO.1996.14.4.1252. View

12.

Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D . The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001; 97(11):3370-9. DOI: 10.1182/blood.v97.11.3370. View

13.

Philip T, Hartmann O, Pinkerton R, Zucker J, Gentet J, Lamagnere J . Curability of relapsed childhood B-cell non-Hodgkin's lymphoma after intensive first line therapy: a report from the Société Française d'Oncologie Pédiatrique. Blood. 1993; 81(8):2003-6. View

14.

Harris N, Jaffe E, STEIN H, Banks P, Chan J, Cleary M . A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84(5):1361-92. View

15.

Goldman S, Smith L, Galardy P, Perkins S, Frazer J, Sanger W . Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. Br J Haematol. 2014; 167(3):394-401. PMC: 4198418. DOI: 10.1111/bjh.13040. View

16.

Cairo M, Shen V, Krailo M, Bauer M, Miser J, Sato J . Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report. J Pediatr Hematol Oncol. 2001; 23(1):30-8. DOI: 10.1097/00043426-200101000-00008. View

17.

Satwani P, Jin Z, Martin P, Bhatia M, Garvin J, George D . Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and.... Leukemia. 2014; 29(2):448-55. DOI: 10.1038/leu.2014.194. View

18.

Cairo M, Gerrard M, Sposto R, Auperin A, Pinkerton C, Michon J . Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2006; 109(7):2736-43. PMC: 1852225. DOI: 10.1182/blood-2006-07-036665. View

19.

MURPHY S . Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980; 7(3):332-9. View

20.

Gross T, Hale G, He W, Camitta B, Sanders J, Cairo M . Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant. 2009; 16(2):223-30. PMC: 2911354. DOI: 10.1016/j.bbmt.2009.09.021. View